Skip to main content

Advertisement

SpringerLink
Log in

Arrhythmias during and after zoledronic acid infusion patients with bone metastasis

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Zoledronic acid (ZA) is one of the important bisphosphonates which is widely used in bone metastatic cancer and osteoporotic patients. In a few studies, it has been reported that treatment with bisphosphonates was associated with an increased risk of atrial fibrillation. We aimed to evaluate the arrhythmias that developed during and immediately after infusion of the ZA. Fifty-two bone metastatic patients were included in the study group. All patients had 24-h Holter monitorization during the first dose ZA infusion day. All of the patients had 4-h basal cardiac rhythm records before ZA infusion and about 19 h after infusion. A short survey including demographic data and past medical history has been completed. None of patients had clinically important arrhythmias before ZA infusion. We divided arrhythmias into two groups as supraventricular and ventricular. We evaluated arrhythmias in pre-infusion, during infusion, and post-infusion periods. ZA was administered 4 mg intravenously (IV) in 15 min. Thirty-three of patients (63.5 %) were male and 19 (36.5 %) patients were female. Mean age of the patients was 53.9 ± 11.8 years. Most frequent cancers were breast (25 %) and lung cancer (15.3 %). Twelve (23 %) patients had history of mediastinal radiotherapy. In basal records, we detected that twenty-four (46 %) of patients had supraventricular premature complexes (SVPC) or ventricular premature complexes (VPC). Fifteen (28.8 %) of patients had SVPC and fourteen (26.9 %) had VPC during infusion period. After infusion period, 48 (92.3 %) of patients had SVPC and 41 (78.8 %) had VPC. Only 3 patients had no arrhythmia after infusion. Three patients had sinus arrhythmia and two had Mobitz type 2 atrioventricular blocks after infusion. One patient, who had no history of comorbidities and had SVPC in the basal records, developed atrial fibrillation that was refractory to medical cardioversion after 10 days of seventh dose of ZA infusion. In this study, we found that both SVPC and VPC increased in cancer patients treated with ZA. Furthermore, ZA may induce clinically important arrhythmias.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res. 2003;9:2394–9.

    PubMed  CAS  Google Scholar 

  2. Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med. 2009;265:581–92.

    Article  PubMed  CAS  Google Scholar 

  3. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008;168:826–31.

    Article  PubMed  CAS  Google Scholar 

  4. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–22.

    Article  PubMed  CAS  Google Scholar 

  5. Sorensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008;336:813–6.

    Article  PubMed  Google Scholar 

  6. Bunch TJ, Anderson JL, May HT, et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol. 2009;103:824–8.

    Article  PubMed  CAS  Google Scholar 

  7. Erichsen R, Christiansen CF, Frøslev T, Jacobsen J, Sørensen HT. Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study. Br J Cancer. 2011;105:881–3.

    Article  PubMed  CAS  Google Scholar 

  8. Wilkinson GS, Baillargeon J, Kuo YF, Freeman JL, Goodwin JS. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. J Clin Oncol. 2010;28:4898–905.

    Article  PubMed  CAS  Google Scholar 

  9. Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self controlled case-series safety analysis. PLoS ONE. 2009;4:e4720.

    Article  PubMed  Google Scholar 

  10. McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126:13–20.

    Article  PubMed  CAS  Google Scholar 

  11. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–809.

    Article  PubMed  CAS  Google Scholar 

  12. Arslan C, Aksoy S, Dizdar O, Dede DS, Harputluoglu H, Altundag K. Zoledronic acid and atrial fibrillation in cancer patients. Support Care Cancer. 2011;19:425–30.

    Article  PubMed  Google Scholar 

  13. Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf. 2009;32:219–28.

    Article  PubMed  CAS  Google Scholar 

  14. Frame LH, Page RL, Hoffman BF. Atrial reentry around an anatomic barrier with a partially refractory excitable gap. a canine model of atrial flutter. Circ Res. 1986;58:495–511.

    Article  PubMed  CAS  Google Scholar 

  15. Kamjoo K, Uchida T, Ikeda T, et al. Importance of location and timing of electrical stimuli in terminating sustained functional reentry in isolated swine ventricular tissues: evidence in support of a small reentrant circuit. Circulation. 1997;96:2048–60.

    Article  PubMed  CAS  Google Scholar 

  16. Antzelevitch C, Burashnikov A. Overview of basic mechanisms of cardiac arrhythmia. Card Electrophysiol Clin. 2011;3:23–45.

    Article  PubMed  Google Scholar 

  17. Messineo FC. Ventricular ectopic activity: prevalence and risk. Am J Cardiol. 1989;64:53J–6J.

    Article  PubMed  CAS  Google Scholar 

  18. Bigger JT Jr, Dresdale FJ, Heissenbuttel RH, Weld FM, Wit AL. Ventricular arrhythmias in ischemic heart disease: mechanism, prevalence, significance, and management. Prog Cardiovasc Dis. 1977;19:255.

    Article  PubMed  Google Scholar 

  19. Kantor RJ, Garson A. Arrhythmias in congenital heart disease. In: Podrid PJ, Kowey PR, editors. Cardiac arrhythmia: mechanisms, diagnosis, and management. Baltimore: Williams & Wilkins; 1995. p. 1131.

    Google Scholar 

  20. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort the Framingham Heart Study. JAMA. 1994;271:840–4.

    Article  PubMed  CAS  Google Scholar 

  21. Zhuang J, Wang Y, Tang K, et al. Association between left atrial size and atrial fibrillation recurrence after single circumferential pulmonary vein isolation: a systematic review and meta-analysis of observational studies. Europace. 2012;14:638–45.

    Article  PubMed  Google Scholar 

  22. Lainscak M, Dagres N, Filippatos GS, Anker SD, Kremastinos DT. Atrial fibrillation in chronic non-cardiac disease: where do we stand? Int J Cardiol. 2008;128:311–5.

    Article  PubMed  Google Scholar 

  23. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60:2263–70.

    Article  PubMed  CAS  Google Scholar 

  24. Takahashi N, Kume O, Wakisaka O, et al. Novel strategy to prevent atrial fibrosis and fibrillation. Circ J. 2012;76:2318–26.

    Article  PubMed  CAS  Google Scholar 

  25. Köroğlu S, Tuncer C, Acar G. Relation of inflammatory and oxidative markers to the occurrence and recurrence of persistent atrial fibrillation. Turk Kardiyol Dern Ars. 2012;40:499–504.

    Article  PubMed  Google Scholar 

  26. Du RH, Yi HW, Dai DZ, Tang WH, Dai Y. Inflammatory factors that contribute to upregulation of ERG and cardiac arrhythmias are suppressed by CPU86017, a class III antiarrhythmic agent. J Pharm Pharmacol. 2008;60:1089–95.

    Article  PubMed  CAS  Google Scholar 

  27. Corrado A, Santoro N, Cantatore FP. Extra-skeletal effects of bisphosphonates. Joint Bone Spine. 2007;74:32–8.

    Article  PubMed  CAS  Google Scholar 

  28. Wolf AM, Rumpold H, Tilg H, Gastl G, Gunsilius E, Wolf D. The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica. 2006;91:1165–71.

    PubMed  CAS  Google Scholar 

  29. Scheller EL, Hankenson KD, Reuben JS, Krebsbach PH. Zoledronic acid inhibits macrophage SOCS3 expression and enhances cytokine production. J Cell Biochem. 2011;112:3364–72.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Ankara Numune Education and Research Hospital, 06100, Sihhiye, Ankara, Turkey

    Ozan Yazici, Nuriye Ozdemir, Mehmet Ali Nahit Sendur, Zafer Arik, Sebnem Yaman, Tulay Eren, Dogan Uncu & Nurullah Zengin

  2. Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    Sercan Aksoy

  3. Cardiology Department, Ankara Numune Research and Education Hospital, Ankara, Turkey

    Ozgul Ucar & Mevlut Demir

Authors
  1. Ozan Yazici
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sercan Aksoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ozgul Ucar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nuriye Ozdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mevlut Demir
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mehmet Ali Nahit Sendur
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zafer Arik
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sebnem Yaman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tulay Eren
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Dogan Uncu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Nurullah Zengin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ozan Yazici.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yazici, O., Aksoy, S., Ucar, O. et al. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis. Med Oncol 30, 609 (2013). https://doi.org/10.1007/s12032-013-0609-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0609-5

Keywords

Search

Navigation